Long-term outcome following Intensive Residential Treatment of Obsessive-Compulsive Disorder

Journal of Psychiatric Research

Volumn 43, Issue 13, 2009, Pages 1118-1123

  Stewart, S Evelyn ^a,b,c   Stack, Denise Egan ^a   Tsilker, Svetlana ^a   Alosso, Jen ^a   Stephansky, Matt ^a   Hezel, Dianne M ^a,b   Jenike, Eric A ^a,b   Haddad, Stephen A ^b   Kant, Jared ^b   Jenike, Michael A ^a,b,c  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Effectiveness; Inpatient; Intensive Residential Treatment; Long term outcome; Obsessive Compulsive Disorder

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR THERAPY; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOME ENVIRONMENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RELAPSE; RESIDENTIAL CARE; SCORING SYSTEM; SOCIAL ADAPTATION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; WORK ENVIRONMENT;

EMPLOYMENT; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; RESIDENTIAL FACILITIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 68949207889     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.03.012     Document Type: Article

References (31)

1. Ayuso-Mateos JL. Global Burden of obsessive-compulsive disorder in the year 2000. World Health Organization; 2006.
2. Bandelow B. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectrums 13 9 Suppl 14 (2008) 37-46
3. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 4 (1961) 561-571
4. Broatch J.W. Obsessive-compulsive disorder: adding value to treatment through patient support groups. International Clinical Psychopharmacology 11 Suppl. 5 (1996) 89-94
5. Burt T., and Ishak W. Outcome measurement in mood disorders. In: Ishak W., Burt T., and Sederer L. (Eds). Outcome measurement in psychiatry (2002), American Psychiatric Publishing, Washington, DC 164-165
6. Cottraux J., Note I., Yao S.N., Lafont S., Note B., Mollard E., et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychotherapy and Psychosomatics 70 6 (2001) 288-297
7. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 162 1 (2005) 151-161
8. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48 9 (1991) 851-855
9. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The yale-brown obsessive compulsive scale. I. Development, use, and reliability. Archives of General Psychiatry 46 11 (1989) 1006-1011
10. Goodman W.K., Kozak M.J., Liebowitz M., and White K.L. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology 11 1 (1996) 21-29
11. Greenberg B.D., Malone D.A., Friehs G.M., Rezai A.R., Kubu C.S., Malloy P.F., et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 31 11 (2006) 2384-2393
12. Greist J., Chouinard G., DuBoff E., Halaris A., Kim S.W., Koran L., et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry 52 4 (1995) 289-295
13. Hembree E.A., Riggs D.S., Kozak M.J., Franklin M.E., and Foa E.B. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectrums 8 5 (2003) 363-371 81
14. Hohagen F., Winkelmann G., Rasche-Ruchle H., Hand I., Konig A., Munchau N., et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. British Journal of Psychiatry Supplement 35 (1998) 71-78
15. Hollander E., Allen A., Steiner M., Wheadon D.E., Oakes R., and Burnham D.B. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Journal of Clinical Psychiatry 64 9 (2003) 1113-1121
16. Jung H.H., Kim C.H., Chang J.H., Park Y.G., Chung S.S., and Chang J.W. Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: long-term follow-up results. Stereotactic and Functional Neurosurgery 84 4 (2006) 184-189
17. Masellis M., Rector N.A., and Richter M.A. Quality of life in OCD: differential impact of obsessions, compulsions, and depression comorbidity. Canadian Journal of Psychiatry 48 2 (2003) 72-77
18. McKenzie N., and Marks I. Routine monitoring of outcome over 11 years in a residential behavioural psychotherapy unit. Psychotherapy and Psychosomatics 72 4 (2003) 223-227
19. McLean P.D., Whittal M.L., Thordarson D.S., Taylor S., Sochting I., Koch W.J., et al. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. Journal of Consulting and Clinical Psychology 69 2 (2001) 205-214
20. Montgomery S.A., Kasper S., Stein D.J., Bang Hedegaard K., and Lemming O.M. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology 16 2 (2001) 75-86
21. Mundt J.C., Marks I.M., Shear M.K., and Greist J.H. The work and social adjustment scale: a simple measure of impairment in functioning. British Journal of Psychiatry 180 (2002) 461-464
22. Romano S., Goodman W., Tamura R., and Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. Journal of Clinical Psychopharmacology 21 (2001) 46-52
23. Simpson H.B., Franklin M.E., Cheng J., Foa E.B., and Liebowitz M.R. Standard criteria for relapse are needed in obsessive-compulsive disorder. Depression and Anxiety 21 1 (2005) 1-8
24. Simpson H.B., Huppert J.D., Petkova E., Foa E.B., and Liebowitz M.R. Response versus remission in obsessive-compulsive disorder. Journal of Clinical Psychiatry 67 2 (2006) 269-276
25. SPSS for Windows 15.0. Chicago: SPSS Inc. 2006.
26. Stewart S.E., Stack D.E., Farrell C., Pauls D.L., and Jenike M.A. Effectiveness of intensive residential treatment (IRT) for severe, refractory obsessive-compulsive disorder. Journal of Psychiatric Research 39 6 (2005) 603-609
27. Stewart S.E., Yen C.H., Stack D.E., and Jenike M.A. Outcome predictors for severe obsessive-compulsive patients in intensive residential treatment. Journal of Psychiatric Research 40 6 (2006) 511-519
28. Storch E.A., Merlo L.J., Larson M.J., Marien W.E., Geffken G.R., Jacob M.L., et al. Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. Comparative Psychiatry 49 1 (2008) 35-42
29. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry 1991;48(8):730-8.
30. Tollefson G.D., Rampey Jr. A.H., Potvin J.H., Jenike M.A., Rush A.J., kominguez R.A., et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry 51 7 (1994) 559-567
31. van Oppen P., van Balkom A.J., de Haan E., and van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. Journal of Clinical Psychiatry 66 11 (2005) 1415-1422